

**RESPONSE UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1618**

Attorney Docket No. 9022-41

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Maurer et al.
Application Serial No.: 10/767,352
Filed: January 30, 2004
For: *Oral Compositions of Fenretinide Having Increased Bioavailability and Methods of Using the Same*

Confirmation No.: 4884
Group Art Unit: 1618
Examiner: Blessing M. Fubara

Date: August 13, 2009

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT AFTER FINAL ACTION
ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION (RCE)**

Sir/Madam:

This Amendment is submitted in reply to the final Office Action dated April 15, 2009 and accompanies a Request for Continued Examination (RCE). Applicants respectfully request reconsideration of the application in view of the remarks submitted herein.

It is not believed that any fee(s), including fees for additional claims, are required, beyond those that may otherwise be provided for in documents accompanying this submission. In the event, however, that any requests, petitions or extensions of time for the accompanying response are required to prevent abandonment of this application, Applicants submit that such an extension is also hereby petitioned for under 37 C.F.R. §1.136(a) and/or a request be granted pursuant to 37 C.F.R. §1.114. Any additional fees believed to be due in connection with this submission may be charged to our Deposit Account No. 50-0220, or any overpayment may be credited to the same.

Amendments to the Claims begin on page 2 of this document.

Remarks/Arguments begin on page 6 of this document.